Noopept
Also known as · GVS-111 · N-phenylacetyl-L-prolylglycine ethyl ester
Overview
An orally active dipeptide nootropic developed in Russia as a more potent analogue of piracetam, studied for mild cognitive impairment and post-concussive symptoms.
Research profile · for clinicians
Based on research: human data exist but come almost entirely from Russian clinical literature. Reported effects centre on attention, memory consolidation, and anxiolysis in mild cognitive disorders.
Mechanism of action
Metabolised to cycloprolylglycine, an endogenous neuropeptide that modulates AMPA receptor function and raises hippocampal NGF and BDNF expression.
Research record
- [01]Russian randomised comparisons with piracetam in mild cognitive impairment.
- [02]Antioxidant and anti-inflammatory effects reported in neuronal culture.
Selected references
Noopept in the treatment of mild cognitive impairment
Neurosci. Behav. Physiol., 2009
Research deep dive
Every cited study, explained
Plain-language walkthroughs of each reference, with direct PubMed links and dosing-literature context.